Plasma cell-free RNA (cfRNA) is a promising source of non-invasive biomarkers, but its clinical translation is hindered by technical challenges and a lack of protocol standardization, which ...

Radiotherapy augments immunotherapy, yet conventional 2 Gy x-ray fractions largely induce apoptosis, whereas robust ...

RNA therapies hold tremendous promise for treating genetic eye diseases. However, their development is limited by the lack of ...

The New Mexico Cancer Center Foundation offered free screenings for lung cancer. The center says the calendar for 2026 has filled. If you need or feel like you need a lung cancer screening, you should ...

SAN ANTONIO, Aug. 3, 2026 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced that it has executed a strategic ...

The Panorama of cancers in France 2026 highlights a contrasting evolution. In 2023, lung cancer represents: 52,777 new cases, making it the 2nd most common cancer in men and the 3rd most common in ...

Stand Up To Cancer (SU2C) awarded funding to three research teams to develop noninvasive tests for the early detection of lung cancer, according to the organization. The awards represent the first ...

SAN ANTONIO--(BUSINESS WIRE)--$BIAF #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early ...

SAN ANTONIO, July 27, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today ...